NCT05345717View on ClinicalTrials.gov

Novel Desensitization Kidney Transplantation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2026

Conditions
Kidney TransplantationEnd Stage Kidney Disease (ESRD)
Interventions
DRUG

Belatacept Injection

Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy

Trial Locations (1)

60637

RECRUITING

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT05345717 - Novel Desensitization Kidney Transplantation | Biotech Hunter | Biotech Hunter